Tempus makes $1.5B bet to corner cancer-test market
Tempus AI (TEM) spent three years selling someone elses cancer test. On Monday, July 20, it decided to just buy…
12,410$
5,80%
Echtzeit-Aktienkurs Personalis Inc.
Bid:
Ask:
Nachrichten zur Personalis Inc. Aktie
Personalis, Inc. (PSNL) M&A Call Transcript
…
Tempus to acquire Personalis for $1.5 billion
Tempus AI said ?on Monday it would acquire ?Personalis for about $1.5 billion to bringing its cancer test ?to ?the…
Tempus AI to acquire cancer-monitoring firm Personalis for $1.5B
Tempus AI (NASDAQ:TEM) will acquire Personalis (NASDAQ:PNSL) in a stock deal valued at $1.5 billion, expanding its reach in the…
Personalis Inc.: Präzisionsmedizin vor dem kommerziellen Wendepunkt: Kann diese Biotech-Wette aufgehen?
Das Geschäftsmodell transformiert sich rasant vom reinen Forschungsdienstleister zum klinischen Diagnostik-Spezialisten, dessen ultra-sensitive Flüssigbiopsien (NeXT Personal ) Krebsrückfälle Monate...…
Personalis CEO Sells 100,000 Company Shares Worth $1.1 Million. What Does That Mean for Investors?
This cancer genomics specialist, serving major biopharma and research clients, reported a notable insider sale in its latest SEC filing.…
Pivotal-Point Nachverfolgung Personalis (PSNL): Erweiterte Medicare-Erstattung für „NeXT Personal“ öffnet gigantischen US-Absatzmarkt
Personalis ist ein Vorreiter in der Präzisionsonkologie und bietet ultra-sensitive Gensequenzierungen zur Krebsüberwachung an. Am 13. Mai reagierte die Aktie…
Why is Personalis stock surging today?
Why is Personalis stock surging today?…
Personalis: Medicare-Erstattung für Brustkrebsüberwachung liefert Auftrieb – Analysten sehen 20 %-Chance!
Personalis (PSNL) hat sich als Diagnostikunternehmen auf die Präzisionsonkologie spezialisiert. Eines der Kernprodukte ist NeXT Personal, das zur Erkennung minimaler…
Personalis reiterates 2025 revenue guidance of $80M-$90M with focus on MRD testing growth
…
Personalis, Inc. (PSNL) Q1 2025 Earnings Call Transcript
…
Exciting Technology At Personalis, But Profitability Eludes Them
…
Tempus AI, Inc (TEM) Expands Partnership with Personalis to Advance Ultra-Sensitive MRD Testing for Biopharma
We recently compiled a list of the Top 12 AI Stock News and Ratings Dominating Wall Street. In this article,…
Personalis, Inc. (PSNL) Q3 2024 Earnings Call Transcript
…
Global Gene Panel Market Size To Worth USD 4.46 Billion by 2033 | CAGR of 13.75%
The Global Gene Panel Market Size was Valued at USD 1.23 Billion in 2023 and the Worldwide Gene Panel Market…
Personalis, Inc. (PSNL) Q2 2024 Earnings Call Transcript
…
Myriad Genetics (MYGN) Expands in MRD Testing With New Collab
Myriad Genetics (MYGN) inks an agreement with Personalis to cross-license patent estates covering tumor-informed approaches to detect minimal residual disease.…
Personalis executive sells $1,297 in company stock By Investing.com
Personalis executive sells $1,297 in company stock…
Personalis Inc executive sells over $2,300 in stock By Investing.com
Personalis Inc executive sells over $2,300 in stock…
Personalis, Inc. (PSNL) Q1 2024 Earnings Call Transcript
…
Needham raises Personalis stock target to $3.50, maintains buy rating By Investing.com
Needham raises Personalis stock target to $3.50, maintains buy rating…
Personalis, Inc. (PSNL) Q4 2023 Earnings Call Transcript
…